Highlights

  • Neurotech International Ltd rose 7.14% to AUD 0.015 as of 11 August 2026.
  • Neurotech International said on 14 July 2026 that the US FDA had cleared an Investigational New Drug application for NTI164, opening a pathway for a US paediatric study. A day later, the company announced a AUD 3.15 million R&D tax incentive Loan .
  • FDA clearance changes the development discussion from preparation to execution in the US. The additional funding support is also relevant because clinical programs require sustained Capital before any commercial Revenue can emerge.
  • US trial initiation, patient recruitment, Phase 3 autism program progress and future clinical data are the main catalysts.

For Neurotech International, regulatory clearance matters more than a green day on the screen. The stock rose 7.14% to AUD 0.015 as of 11 August 2026, but the more consequential development came in July, when NTI164 cleared a US FDA step that opens the door to a paediatric clinical study.

Recent Developments

Neurotech International said on 14 July 2026 that the US FDA had cleared an Investigational New Drug application for NTI164, opening a pathway for a US paediatric study. A day later, the company announced a AUD 3.15 million R&D tax incentive loan.

Why It Matters

FDA clearance changes the development discussion from preparation to execution in the US. The additional funding support is also relevant because clinical programs require sustained capital before any commercial revenue can emerge.

Investment requirements remain tied to the milestones and funding needs outlined above.

The Assets described above remain central to the company's strategic value.

Company Overview

Neurotech International is a clinical-stage biotechnology company developing NTI164 for paediatric neurological and neurodevelopmental disorders, including autism spectrum disorder.

Financial Snapshot

As of 11 August 2026, Neurotech International Ltd was quoted at AUD 0.015, up 7.14% for the session. Turnover was AUD 62,988, while Market Capitalisation stood at approximately AUD 19.84 mn.

Over one year, the stock was -11.77%. The daily gain therefore needs to be read alongside the longer-term trend rather than treated as a standalone change in the underlying Business .

Cash Flow remains an important measure of funding capacity and operating progress.

Earnings remain an important measure of whether the business model is gaining Operating Leverage .

What to Watch

US trial initiation, patient recruitment, Phase 3 autism program progress and future clinical data are the main catalysts.

Risks

Clinical outcomes, regulatory requirements, funding needs and the absence of approved-product revenue remain material risks.

What Could Move NTI164 Deeper Into US Development

For Neurotech International Ltd, the next re-rating will depend on measurable delivery rather than the size of one trading-day move. The milestones outlined above provide the clearest test of whether recent market interest can be supported by operating, project or clinical progress.